Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T H Fagerlund

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Acta Anaesthesiologica Scandinavica|February 13, 2001
No pain relief from codeine...? An introduction to pharmacogenomicsT H Fagerlund, O Braaten
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|April 30, 1983
[Zinc deficiency as a complication of Crohn disease]T H Fagerlund, D G Dahl
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 30, 1996
[Analgesic effect of ketamine in a patient with neuropathic pain]I Oye, T Rabben, T H Fagerlund
Clinical Genetics|May 1, 1995
A simple method to detect the RYR1 mutation G1021A, a cause of malignant hyperthermia susceptibilityA Alestrøm, T H Fagerlund, K Berg
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|August 8, 2001
[Future pain treatment]L J Rygh, T H Fagerlund, F Svendsen
Clinical Genetics|December 1, 1996
Recombination between the postulated CCD/MHE/MHS locus and RYR1 gene markersT H Fagerlund, G Islander, E Ranklev-Twetman, et al.
Clinical Genetics|June 1, 1997
Malignant hyperthermia susceptibility, an autosomal dominant disorder?T H Fagerlund, G Islander, E Ranklev Twetman, et al.
Clinical Genetics|July 1, 1995
A search for three known RYR1 gene mutations in 41 Swedish families with predisposition to malignant hyperthermiaT H Fagerlund, G Islander, E R Twetman, et al.
Clinical Genetics|March 31, 1998
Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutationT H Fagerlund, H Ording, D Bendixen, et al.
Nature Genetics|September 1, 1993
Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermiaK A Quane, J M Healy, K E Keating, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Acta Anaesthesiologica Scandinavica|February 13, 2001
No pain relief from codeine...? An introduction to pharmacogenomicsT H Fagerlund, O Braaten
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|April 30, 1983
[Zinc deficiency as a complication of Crohn disease]T H Fagerlund, D G Dahl
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 30, 1996
[Analgesic effect of ketamine in a patient with neuropathic pain]I Oye, T Rabben, T H Fagerlund
Clinical Genetics|May 1, 1995
A simple method to detect the RYR1 mutation G1021A, a cause of malignant hyperthermia susceptibilityA Alestrøm, T H Fagerlund, K Berg
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|August 8, 2001
[Future pain treatment]L J Rygh, T H Fagerlund, F Svendsen
Clinical Genetics|December 1, 1996
Recombination between the postulated CCD/MHE/MHS locus and RYR1 gene markersT H Fagerlund, G Islander, E Ranklev-Twetman, et al.
Clinical Genetics|June 1, 1997
Malignant hyperthermia susceptibility, an autosomal dominant disorder?T H Fagerlund, G Islander, E Ranklev Twetman, et al.
Clinical Genetics|July 1, 1995
A search for three known RYR1 gene mutations in 41 Swedish families with predisposition to malignant hyperthermiaT H Fagerlund, G Islander, E R Twetman, et al.
Clinical Genetics|March 31, 1998
Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutationT H Fagerlund, H Ording, D Bendixen, et al.
Nature Genetics|September 1, 1993
Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermiaK A Quane, J M Healy, K E Keating, et al.
Pageof 1